Baricitinib is currently being studied for the treatment of atopic dermatitis. Baricitinib is part of the family of oral Janus kinase inhibitors that are an emerging modality in the treatment of chronic allergic inflammatory disorders due to their ability to inhibit signaling of multiple pathways of cytokines. We discussed in another blog post, Abrocitinib which is […]
New Urticaria Treatment Options being studied
New urticaria treatment options are currently being studied for patients with chronic spontaneous urticaria. Currently the only approved biologic medication approved for this condition is Xolair. Several medications are also being used off label and novel biologics are currently in development. Here we discuss them: Dupilumab– In preclinical studies, dupilumab (Dupixent) blocked several functions of […]
Capsaicin for Nonallergic Rhinitis
Capsaicin nasal spray may be an effective treatment for patients who have nonallergic rhinitis. A significant proportion (25-30%) of patients suffering from rhinitis have nasal symptoms without an infection or allergies, this is referred to nonallergic rhinitis. Up to 50% of these patients have idiopathic rhinitis after excluding work, elderly, gustatory, hormonal and drug induced […]
Allegra during Pregnancy, is it safe?
Allegra during pregnancy, is it safe to use? Antihistamines are commonly prescribed to pregnant women. Cetirizine (Zyrtec) and loratadine (Claritin) are considered safe to use during pregnancy, but there are few data on the safety of Allegra (fexofenadine) for the fetus. A study published in the JAMA Pediatrics titled “Association between fexofenadine use during pregnancy […]
Indacaterol for severe asthma
Indacaterol is an ultra long acting beta agonist that is currently only FDA approved to treat COPD. Indacaterol containing inhalers have shown promise in 2 recent phase 3 trials in patients with severe uncontrolled asthma. For both trials, the endpoint was measured on spirometry and it studied the FEV1 after 26 weeks of treatment. In […]
Abrocitinib for Atopic Dermatitis by Pfizer
Abrocitinib is currently being developed by Pfizer for the treatment of atopic dermatitis (eczema). It is an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor. The JAK/STAT pathway is an important factor in inflammation and itch in atopic dermatitis. There are multiple receptors and signaling cascades involved in eczema related inflammation and itch, one of these […]
Generic Dymista Now Available
Generic Dymista is now available. Dymista consists of 2 ingredients that treat allergic rhinitis, fluticasone and azelastine. Apotex is a Canadian pharmacy who will be manufacturing this product. Dymista is approved for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both azelastine hydrochloride and […]
Pataday OTC now approved for Eye Allergies
The US Food and Drug Administration approved Pataday to become OTC. It approved Pataday OTC through a process called a prescription to OTC switch. Pataday Twice Daily Relief (olopatadine HCL ophthalmic solution/drops 0.1%) is for the temporary relief of itchy and red eyes due to pollen ragweed, grass, animal hair or dander and Pataday Once […]
New Sublingual Tree Tablet
A new sublingual tree tablet is currently being developed for the treatment of tree pollen induced allergic rhinoconjunctivitis. Allergic rhinitis is estimated to affect 500 million individuals worldwide and is considered a global health problem. It leads to lower school and work performance. Allergic rhinitis is also a risk factor for asthma development. Currently allergy […]
Ryaltris Nasal Spray for Allergic Rhinitis
Ryaltris is a new nasal spray (formerly GSP301) that is being investigated by Glenmark Pharmaceuticals for the treatment of seasonal allergic rhinitis in patients 12 years and older. Ryaltris consists of 2 drugs, the first one is olopatadine hydrochloride, a nasal antihistamine, which is the medication used in Patanase nasal spray. The second medication […]